Electromed Tidigare resultatutveckling
Tidigare kriterier kontrolleras 6/6
Electromed har ökat intäkterna med en genomsnittlig årlig takt på 33.8%, medan Medical Equipment -branschen såg intäkterna växer på 15.3% årligen. Intäkterna har varit växande med en genomsnittlig takt på 14.5% per år. Electromed s avkastning på eget kapital är 20.6% och den har en nettomarginal på 14.1%.
Viktig information
33.84%
Tillväxttakt i vinsten
34.24%
Tillväxttakt för EPS
| Medical Equipment Tillväxt i branschen | 8.90% |
| Intäkternas tillväxttakt | 14.54% |
| Avkastning på eget kapital | 20.55% |
| Nettomarginal | 14.08% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
ELMD: Bronchiectasis Exposure And Margin Execution Will Support Future Upside
Analysts have nudged their price target on Electromed stock higher to $40 from $38, citing record Q3 results with 18.4% revenue growth, strong operating leverage, and confidence in continued double-digit expansion supported by broader adoption, payer coverage, and an underpenetrated bronchiectasis market. What's in the News Analysts raised their price target on Electromed stock to $40 from $38, citing record Q3 results and 18.4% revenue growth.
ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside
Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.ELMD: Refreshed Discount Rate And P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Electromed by $2, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E that support a slightly higher fair value estimate. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rates and future P/E, which together suggest more support for the current valuation than before.ELMD: Share Repurchases And Margin Execution Will Support Future Upside
Analysts have raised their price target on Electromed by $2 to reflect updated assumptions around revenue growth, profit margin and long-term P/E expectations. Analyst Commentary Recent research points to a more cautious tone around Electromed, even alongside the higher price target.ELMD: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have increased their price target on Electromed by $2 to $36, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as key factors behind the change. Analyst Commentary While the new US$36 price target reflects updated valuation work, some bearish analysts are still flagging risk factors that they believe limit upside for Electromed at current levels.ELMD: Share Repurchases Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target on Electromed up by $1 to $37, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E after the latest Street research. Analyst Commentary Recent Street research has focused on how Electromed's fundamentals line up with the revised fair value assumptions and the updated $37 target.ELMD: Completed Share Buyback Will Support Future Upside In Undervalued Shares
Analysts have adjusted their price target on Electromed to reflect a fair value of $36.00, citing only minor tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E. Their overall valuation view remains largely unchanged.ELMD: Share Buyback And Higher Margin Outlook Will Support Future Upside
Analysts have kept their price target for Electromed steady at US$34.00, reflecting updated views on slightly higher projected revenue growth and profit margins, along with a marginally adjusted discount rate and future P/E assumption. What's in the News Completed the repurchase of 40,848 shares, representing 0.49% of the company, for US$1 million under the share buyback announced on September 9, 2025 (Key Developments).ELMD: Higher Margin Outlook And Share Buyback Will Support Upside Potential
Analysts have raised their fair value estimate for Electromed from US$29 to US$34, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Between September 9, 2025 and September 30, 2025, Electromed repurchased 40,848 shares for US$1 million, representing 0.49% of shares.ELMD: Share Repurchase Program Will Support Future Upside In Undervalued Shares
Analysts have nudged their price target for Electromed slightly higher to approximately $36.00 per share, citing modest improvements in discount rate assumptions and forward valuation metrics while largely reaffirming their prior outlook. What's in the News Completed a share repurchase tranche totaling 40,848 shares, or about 0.49 percent of outstanding shares, for approximately $1 million under the buyback program announced September 9, 2025 (company filing) Valuation Changes Fair Value Estimate reaffirmed at approximately $36.00 per share, reflecting no material change in intrinsic value assumptions.ELMD: Share Repurchase Plan And Expanding Outlook Will Lift Share Price
Analysts have raised their price target for Electromed from $35.25 to $36.00. They cite an improved outlook for future revenue growth, despite a slightly higher discount rate and marginally lower profit margin projections.ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher
Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
The Triple Down On Bronchiectasis Campaign Will Expand SmartVest Clearway's Market Reach
Diversifying beyond homecare and investing in sales efforts may drive revenue growth and improve earnings through expanded market channels and effective sales execution.Fördelning av intäkter och kostnader
Hur Electromed tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 72 | 10 | 42 | 1 |
| 31 Dec 25 | 69 | 9 | 41 | 1 |
| 30 Sep 25 | 66 | 8 | 40 | 1 |
| 30 Jun 25 | 64 | 8 | 39 | 1 |
| 31 Mar 25 | 61 | 7 | 38 | 1 |
| 31 Dec 24 | 60 | 7 | 36 | 1 |
| 30 Sep 24 | 57 | 6 | 35 | 1 |
| 30 Jun 24 | 55 | 5 | 34 | 1 |
| 31 Mar 24 | 53 | 4 | 34 | 1 |
| 31 Dec 23 | 52 | 4 | 34 | 1 |
| 30 Sep 23 | 50 | 3 | 33 | 1 |
| 30 Jun 23 | 48 | 3 | 32 | 1 |
| 31 Mar 23 | 46 | 3 | 30 | 1 |
| 31 Dec 22 | 44 | 2 | 29 | 1 |
| 30 Sep 22 | 42 | 2 | 28 | 1 |
| 30 Jun 22 | 42 | 2 | 27 | 1 |
| 31 Mar 22 | 40 | 2 | 26 | 1 |
| 31 Dec 21 | 39 | 2 | 25 | 1 |
| 30 Sep 21 | 38 | 2 | 24 | 2 |
| 30 Jun 21 | 36 | 2 | 22 | 2 |
| 31 Mar 21 | 33 | 3 | 21 | 2 |
| 31 Dec 20 | 33 | 4 | 21 | 2 |
| 30 Sep 20 | 32 | 4 | 20 | 1 |
| 30 Jun 20 | 32 | 4 | 20 | 1 |
| 31 Mar 20 | 34 | 4 | 20 | 1 |
| 31 Dec 19 | 33 | 4 | 20 | 1 |
| 30 Sep 19 | 32 | 3 | 20 | 1 |
| 30 Jun 19 | 31 | 2 | 20 | 1 |
| 31 Mar 19 | 31 | 2 | 20 | 1 |
| 31 Dec 18 | 30 | 2 | 20 | 0 |
| 30 Sep 18 | 29 | 2 | 20 | 0 |
| 30 Jun 18 | 28 | 2 | 19 | 0 |
| 31 Mar 18 | 28 | 2 | 18 | 0 |
| 31 Dec 17 | 27 | 2 | 18 | 0 |
| 30 Sep 17 | 27 | 2 | 17 | 0 |
| 30 Jun 17 | 26 | 2 | 16 | 1 |
| 31 Mar 17 | 24 | 2 | 16 | 1 |
| 31 Dec 16 | 24 | 1 | 15 | 1 |
| 30 Sep 16 | 23 | 2 | 15 | 1 |
| 30 Jun 16 | 23 | 2 | 14 | 0 |
| 31 Mar 16 | 22 | 2 | 14 | 0 |
| 31 Dec 15 | 21 | 2 | 13 | 0 |
| 30 Sep 15 | 20 | 1 | 12 | 0 |
| 30 Jun 15 | 19 | 1 | 12 | 0 |
Kvalitetsintäkter: ELMD har inkomster av hög kvalitet.
Växande vinstmarginal: ELMD s nuvarande netto vinstmarginaler (14.1%) är högre än förra året (11.7%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: ELMD s intäkter har ökat markant med 33.8% per år under de senaste 5 åren.
Accelererande tillväxt: ELMD s intäktstillväxt under det senaste året ( 41.1% ) överstiger sitt 5-åriga genomsnitt ( 33.8% per år).
Resultat vs industri: ELMD vinsttillväxt under det senaste året ( 41.1% ) översteg Medical Equipment branschen 14.8%.
Avkastning på eget kapital
Hög ROE: ELMD s avkastning på eget kapital ( 20.6% ) anses vara hög.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/15 15:52 |
| Aktiekurs vid dagens slut | 2026/06/15 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Electromed, Inc. bevakas av 6 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |